Department of Gastroenterology, FuShun People's Hospital, Zigong, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Helicobacter. 2021 Oct;26(5):e12843. doi: 10.1111/hel.12843. Epub 2021 Aug 11.
The oral chicken immunoglobulin Y (IgY) as a novel model of immunotherapy to control Helicobacter pylori (H. pylori, Hp) infection has gained much interest in recent years. However, none of the current IgY therapies showed a total eradication of H. pylori on patients.
In this report, the recombinant antigens of H. pylori, including UreB (1710 bp), BabA2 (1269 bp), and FlaA (399 bp), were, respectively, expressed and purified, and then mixed and subjected to immunize laying hens for the preparation of multivalent anti-H. pylori immunoglobulin Y (anti-Hp mIgY). Next, the biological activities of anti-Hp mIgY, including the recognition to antigens and the inhibition on H. pylori growth, were tested. Moreover, to perform a clinical trial, 94 Hp-infected patients, according to the values of C urea breath test and the characteristics of gastroscopy of volunteers, were enrolled to evaluate the effects of dietary anti-Hp mIgY against H. pylori infection. After continuous dietary of anti-Hp mIgY for 2 weeks, the oral administration was terminated. The clinical symptoms of the patients were followed up at 2nd, 4th, and 6th week, respectively, and the C urea breath test were re-examined at 6th week.
The anti-Hp mIgY could bind to recombinant antigens very well, and the titers of anti-Hp mIgY to UreB, Baba2, and FlaA, are 62.5, 125, and 250 μg/ml, respectively. The in vitro antibacterial test showed that the 2 mg/ml of anti-Hp mIgY could completely inhibit the H. pylori growth for 36 h. After a 2-week dietary of anti-Hp mIgY, the value of C urea breath test was significantly decreased by 56.0% (25.9 ± 14.1 vs 11.4 ± 9.78, p < 0.001), the total improvement rate of clinical symptoms in volunteers was 87.3%, and the H. pylori eradication rate was 30.6%.
Two-week dietary of anti-Hp mIgY greatly improved the clinical symptoms and the quality of life of Hp-infected patients, and the H. pylori eradication rate reached up to 30.6%.
口服鸡免疫球蛋白 Y（IgY）作为一种新型免疫疗法模型，近年来在控制幽门螺杆菌（H. pylori，Hp）感染方面引起了广泛关注。然而，目前尚无任何 IgY 疗法能在患者中完全根除 H. pylori。
在本报告中，分别表达和纯化了幽门螺杆菌的重组抗原 UreB（1710 bp）、BabA2（1269 bp）和 FlaA（399 bp），然后将它们混合并用于免疫产卵母鸡以制备多价抗幽门螺杆菌免疫球蛋白 Y（抗-Hp mIgY）。接下来，测试了抗-Hp mIgY 的生物学活性，包括对抗原的识别和对 H. pylori 生长的抑制作用。此外，为了进行临床试验，根据志愿者尿素呼气试验和胃镜检查的结果，招募了 94 名 Hp 感染患者，评估了饮食中抗-Hp mIgY 对 H. pylori 感染的影响。连续饮食抗-Hp mIgY 2 周后，停止口服给药。分别在第 2、4 和 6 周时对患者的临床症状进行随访，并在第 6 周时重新进行尿素呼气试验。
抗-Hp mIgY 能很好地与重组抗原结合，抗-Hp mIgY 对 UreB、Baba2 和 FlaA 的效价分别为 62.5、125 和 250 μg/ml。体外抗菌试验表明，2 mg/ml 的抗-Hp mIgY 可完全抑制 H. pylori 生长 36 小时。饮食抗-Hp mIgY 2 周后，尿素呼气试验值显著降低 56.0%（25.9±14.1 比 11.4±9.78，p<0.001），志愿者的临床症状总改善率为 87.3%，Hp 根除率为 30.6%。
饮食抗-Hp mIgY 2 周可显著改善 Hp 感染患者的临床症状和生活质量，Hp 根除率高达 30.6%。
